Problem
Vulnerable Patients do not have access to life-saving antiviral treatments or preventsive
A critical unmet need exists for immune-independent respiratory protection. Infants, the elderly, and immunocompromised patients often cannot mount protective responses to common viruses, and vaccines are ineffective for them. With antivirals limited to influenza and SARS-CoV-2, over 3 million in the UK lack reliable prevention for community-acquired respiratory viruses (CARVs), facing severe outcomes like >30% mortality for certain pneumonias. Masks and PPE are not viable for infants or those with breathing difficulties.
Our current antiviral approaches are reactive, we are vulnerable to the next viral outbreak
The world remains unprepared for the next pandemic because current antiviral approaches are predominantly reactive: they wait for a specific pathogen to emerge, then depend on vaccines or antivirals that target only a narrow range of viruses. Vaccines are often ineffective in infants and immunocompromised patients. New immune-independent approaches with broad-spectrum activity are therefore needed to prepare for the next pandemic
Negative environemental impact
Hospitalisation, unused medicines, and drug manufacturing impose a linked environmental burden that undermines public health. Hospital care is carbon-intensive—37.9 kg CO₂e per general/acute bed-day and 89.5 kg CO₂e in critical care in England. Up to 50% of dispensed medicines go unused, and improper disposal contaminates water and soil with active pharmaceuticals. Manufacturing adds roughly 52 Mt CO₂e globally and is 55% more emissions-intensive per unit revenue than automotive. Crucially, antiviral residues in waterways create selective pressure that can drive antiviral-resistant viral strains, making future treatment and pandemic preparedness harder.
-
Community-Acquired Respiratory Virus (CARV) cost the UK economy more than £80 billion annually and hundreds of billions of dollars due to healthcare expenditures and lost productivity.
-
With no preventive an 18% increase in hospitalisation from 2025-2035 is estimated to generate additional 1.3 million Kg of CO2-equivalent emissions (link).
-
The healthcare sector is inherently carbon-intensive. For context, the UK National Health Service (NHS) accounts for 4% of total UK carbon emissions annually.
.png)
Our Solutions
NUNAGEN synthetic gene platforms
We have designed and developed 'plug-and-play' synthetic gene platforms that enable:
-
rapid construction of antiviral biobased nanodevices for formulation as preventive
-
delivery via mRNA-lipid nanoparticle formulation for synthesis of antivirals from within the body
Tractions
NUNAGEN patented platforms offer advantages that traditional approaches, such as vaccines and antiviral drugs, cannot achieve:
-
Immune-independent
-
Broad-spectrum
-
Lower dose and less waste
-
Low cost
-
Rapid deployment within the emergence of a new virus
The Impact
The impact on patients, economy, and environment will be profound:
-
Vulnerable patients will be protected against most respiratory viral infections.
-
Pandemic readiness
-
Save millions for health systems
-
Drastically cut the CO2 emission
Born from Global Innovation
Pioneering research from King’s College London turned into industrial reality. We transform intellectual rigor into agile biotech solutions, engineering bespoke gene platforms that redefine the boundaries of preventive medicine and sustainable therapeutics.